RxDoctor Payments Data

Jeffrey Wong, MD

Urology · Alexandria, VANPI 1730167818

Payments from drug & device makers

$3,185in general payments, 2019–2025

Across 92 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$979
  • Calyxo, Inc.$384
  • Astellas Pharma US Inc$314
  • Laborie Medical Technologies Corp.$294
  • Johnson & Johnson$173
  • Pfizer$152
  • plus $889 from 17 others

What the payments were for

  • Travel & lodging$30510%
  • Food & beverage$2,78087%
  • Education$1013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,185 in reported general payments places this provider in the 50th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$562,925
Medicare patients
1,379
Services billed
10,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron100$86,826
Tamsulosin Hcl837$13,932
Alfuzosin Hcl ErAlfuzosin Hcl289$6,185
Testosterone17$6,078
Trospium Chloride ErTrospium Chloride27$5,526
Methenamine Hippurate60$5,233
Finasteride325$4,264
Tolterodine Tartrate ErTolterodine Tartrate32$4,151
Solifenacin Succinate42$4,010
Silodosin44$3,633
Tadalafil21$3,460
Potassium Citrate ErPotassium Citrate21$2,452
Oxybutynin Chloride ErOxybutynin Chloride75$2,376
Estradiol25$1,931
Fesoterodine Fumarate ErFesoterodine Fumarate11$1,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$314$86,826100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 300 urology providers in Virginia.

Other urology in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →